Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9554754 | 0.85 | CA2 (0.49) | SPRALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL9555317 | 0.85 | CA2 (0.49) | SPRALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL9554763 | 0.85 | CA2 (0.49) | SPRALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL29852580 | 0.83 | NPC1 (0.48) | NPC1CNR2ALDH1A1PDK2ALOX5 | |
| SCHEMBL6279672 | 0.80 | NPC1 (0.56) | NPC1CNR2PDK2ALOX5CNR1 | |
| SCHEMBL6279671 | 0.80 | NPC1 (0.56) | NPC1CNR2PDK2ALOX5CNR1 | |
| SCHEMBL12979193 | 0.80 | CNR1 (0.53) | NPC1CNR2PDK2ALOX5CNR1 | |
| SCHEMBL31562993 | 0.80 | CNR1 (0.53) | NPC1CNR2PDK2ALOX5CNR1 | |
| SCHEMBL3575371 | 0.77 | HCRTR1 (0.51) | NPC1CNR2ALDH1A1ALOX5CNR1 | |
| SCHEMBL3575368 | 0.77 | HCRTR1 (0.51) | NPC1CNR2ALDH1A1ALOX5CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044005-B8 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2012-12-05 | — | — | EP | claimed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2024-10-31 | — | — | US | disclosed |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| EP-4095127-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3357911-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-2327696-A1 | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (PR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-2044005-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2010-10-20 | — | — | EP | disclosed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | NPC1 2508/4885SPR 447/4885CNR2 2002/4885 |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | NPC1 2508/4885SPR 447/4885CNR2 2002/4885 |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, EGLN2 | NPC1 2883/4885SPR 491/4885CNR2 1871/4885 |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | NPC1 2508/4885SPR 447/4885CNR2 2002/4885 |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | NPC1 2508/4885SPR 447/4885CNR2 2002/4885 |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | NPC1 2508/4885SPR 447/4885CNR2 2002/4885 |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | NPC1 2508/4885SPR 447/4885CNR2 2002/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | NPC1 2508/4885SPR 447/4885CNR2 2002/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | NPC1 2508/4885SPR 447/4885CNR2 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.